Exelixis Inc. (EXEL)
Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results
Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.
Investing in Exelixis (EXEL)? Don't Miss Assessing Its International Revenue Trends
Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Exelixis: sNDA Cabometyx Expansion Could Provide Revenue Boost
Exelixis, Inc. has a PDUFA date of April 3, 2025, set to decide whether Cabometyx should be approved for the treatment of patients with advanced pancreatic neuroendocrine tumors. U.S. net product revenues of Cabometyx grew by 16% quarter over quarter and a 7% year-over-year increase. Preliminary results from phase 3 STELLAR-303 study, using zanzalintinib in combination with Tecentriq to treat patients with metastatic refractory colorectal cancer that is not microsatellite instability-high or mismatch repair-deficient.
Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues
Exelixis (EXEL) beats on earnings and sales in the second quarter. Its shares are trading up in response to the results.
Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results
In its second-quarter earnings release, Exelixis, Inc. EXEL announced that the final overall survival (OS) analysis for the phase 3 CONTACT-02 trial has been completed.
Exelixis, Inc. (EXEL) Q2 2024 Earnings Call Transcript
Exelixis, Inc. (NASDAQ:EXEL ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Morrissey - President and Chief Executive Officer Christopher Senner - Executive Vice President and Chief Financial Officer Amy Peterson - Executive Vice President, Product Development, Medical Affairs and Chief Medical Officer Dana Aftab - Chief Scientific Officer P.J. Haley - Executive Vice President of Commercial Conference Call Participants Asthika Goonewardene - Truist Jay Olson - Oppenheimer Joyce Zhou - TD Cowen Andy Hsieh - William Blair Silvan Tuerkcan - Citizens JMP David Lebowitz - Citi Michael Riad - Morgan Stanley Jason Gerberry - Bank of America Akash Tewari - Jefferies Alex Bullocks - Barclays Sudan Loganathan - Stephens Chris Shibutani - Goldman Sachs Operator Good day, ladies and gentlemen, and welcome to the Exelixis Second Quarter 2024 Financial Results Conference Call.
Exelixis (EXEL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.31 per share a year ago.
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings
Get a deeper insight into the potential performance of Exelixis (EXEL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
Exelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic versions of Cabometyx in the United States beginning January 2031.
